Considerations in Sequencing BCMA-Targeting Bispecifics and CAR-T Therapies in R/R MM

Opinion
Video

Myeloma specialists discuss considerations they consider when determining how they sequence CAR T-cell therapies and bispecific antibodies.

Recent Videos
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content